Immuneel, HCB and IDIBAPS enter into a collaboration and licensing agreement for CAR T cell therapy EP News Bureau Oct 13, 2020 Immuneel acquires exclusive license to CD19 CAR T product for the potential treatment of B cell malignancies for India
